PENNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
Penumbra Inc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$322.41+1.55 (+0.48%)
Close on Oct 19, 2026
- Market cap
- $12.76B
- P/E (TTM)
- 79.2
- Dividend yield
- –
Penumbra Inc revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Thrombectomy | $258.98M | $253.92M | $254.70M | $236.42M | $230.26M | $226.54M | $220.13M | $204.14M | $203.50M | $187.70M | $190.78M | $179.08M | 66.4% | +12.5% |
| Embolization and Access | $131.07M | $120.84M | – | $118.26M | $109.20M | $97.60M | – | $96.90M | $95.90M | $90.95M | – | $91.87M | 33.6% | +20.0% |
| Vascular | – | – | – | – | – | – | – | – | – | – | – | $99.54M | – | – |
| Neuro | – | – | – | – | – | – | – | – | – | – | – | $171.41M | – | – |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $305.45M | $296.39M | $299.05M | $275.03M | $260.82M | $256.86M | $247.92M | $226.33M | $218.18M | $209.64M | $203.68M | $194.82M | 78.3% | +17.1% |
| International | $84.60M | $78.37M | – | – | $78.64M | $67.28M | – | – | – | – | – | – | 21.7% | +7.6% |
| International | – | – | – | $79.66M | $78.64M | $67.28M | – | $74.71M | $81.22M | $69.01M | – | $76.13M | – | – |
From the segment and revenue-disaggregation notes of Penumbra's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.